TY - JOUR
T1 - Intestinal Microbiota in Cardiovascular Health and Disease
T2 - JACC State-of-the-Art Review
AU - Tang, W. H. Wilson
AU - Backhed, Fredrik
AU - Landmesser, Ulf
AU - Hazen, Stanley L.
N1 - Special Focus Issue: Cardiovascular Health Promotion
The Present and Future
PY - 2019/4/30
Y1 - 2019/4/30
N2 - Despite major strides in reducing cardiovascular disease (CVD) burden with modification of classic CVD risk factors, significant residual risks remain. Recent discoveries that linked intestinal microbiota and CVD have broadened our understanding of how dietary nutrients may affect cardiovascular health and disease. Although next-generation sequencing techniques can identify gut microbial community participants and provide insights into microbial composition shifts in response to physiological responses and dietary exposures, provisions of prebiotics or probiotics have yet to show therapeutic benefit for CVD. Our evolving understanding of intestinal microbiota-derived physiological modulators (e.g., short-chain fatty acids) and pathogenic mediators (e.g., trimethylamine N-oxide) of host disease susceptibility have created novel potential therapeutic opportunities for improved cardiovascular health. This review discusses the roles of human intestinal microbiota in normal physiology, their associations with CVD susceptibilities, and the potential of modulating intestinal microbiota composition and metabolism as a novel therapeutic target for CVD.
AB - Despite major strides in reducing cardiovascular disease (CVD) burden with modification of classic CVD risk factors, significant residual risks remain. Recent discoveries that linked intestinal microbiota and CVD have broadened our understanding of how dietary nutrients may affect cardiovascular health and disease. Although next-generation sequencing techniques can identify gut microbial community participants and provide insights into microbial composition shifts in response to physiological responses and dietary exposures, provisions of prebiotics or probiotics have yet to show therapeutic benefit for CVD. Our evolving understanding of intestinal microbiota-derived physiological modulators (e.g., short-chain fatty acids) and pathogenic mediators (e.g., trimethylamine N-oxide) of host disease susceptibility have created novel potential therapeutic opportunities for improved cardiovascular health. This review discusses the roles of human intestinal microbiota in normal physiology, their associations with CVD susceptibilities, and the potential of modulating intestinal microbiota composition and metabolism as a novel therapeutic target for CVD.
KW - dysbiosis
KW - intestinal microbiota
KW - secondary bile acids
KW - short-chain fatty acid
KW - trimethylamine N-oxide
U2 - 10.1016/j.jacc.2019.03.024
DO - 10.1016/j.jacc.2019.03.024
M3 - Review
C2 - 31023434
SN - 0735-1097
VL - 73
SP - 2089
EP - 2105
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 16
ER -
